Capstone Therapeutics is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing innovative therapies to address unmet medical needs in oncology and rare diseases. The company’s research and development efforts center on leveraging proprietary platforms in gene therapy, immuno-oncology, and targeted biologics. Capstone’s lead candidates include a next-generation CAR-T therapy designed to overcome treatment resistance in hematological malignancies and a novel adeno-associated virus (AAV)–based gene therapy for a rare metabolic disorder.
Since its founding in 2003, Capstone Therapeutics has built a robust pipeline of product candidates, collaborating with academic institutions and biopharma partners to accelerate clinical translation. Capstone’s oncology portfolio features several early-stage molecules aimed at solid tumors, including antibody–drug conjugates and immune checkpoint modulators. In rare diseases, the company’s gene therapy programs seek to establish one-time, durable treatments, with initial trials underway in North America and Europe.
Capstone maintains operations across the United States, Europe and Asia-Pacific, fostering global clinical development and regulatory engagement. The company’s manufacturing capabilities include both in-house cell therapy production and partnerships with contract development and manufacturing organizations (CDMOs), ensuring scalability as programs advance. Strategic alliances with leading research hospitals and specialty centers support Capstone’s adaptive trial designs and patient recruitment initiatives.
Led by Chief Executive Officer Dr. Eleanor Hughes and Chief Scientific Officer Dr. Marco Rodriguez, Capstone Therapeutics combines deep expertise in molecular biology, translational medicine and regulatory strategy. The executive team’s experience spans major pharmaceutical companies and pioneering biotech ventures, positioning Capstone to navigate complex development pathways. With a commitment to scientific rigor and patient-centric innovation, Capstone continues to progress its therapeutic candidates through clinical milestones toward potential commercialization.
AI Generated. May Contain Errors.
Free CAPS Stock Alerts